Loading...
XKRX
016580
Market cap120mUSD
Dec 05, Last price  
11,610.00KRW
1D
0.26%
1Q
10.68%
Jan 2017
-26.75%
Name

Whanin Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:016580 chart
P/E
7.58
P/S
0.68
EPS
1,531.45
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
10.28%
Revenues
259.60b
+12.68%
80,091,447,00092,915,021,00099,386,536,000105,687,139,000110,052,051,320107,221,597,940104,479,910,140120,713,386,090145,397,202,330141,376,271,500147,953,429,460154,664,330,710159,176,971,650171,705,404,970177,775,700,610198,934,734,390230,393,578,986259,596,032,000
Net income
23.38b
-21.47%
11,275,625,00011,154,237,00014,434,550,00017,236,908,00014,612,077,20015,796,562,80014,580,149,40018,805,535,45020,509,660,82016,397,455,15027,172,311,17021,517,959,15018,695,949,84023,387,790,17026,659,600,06023,921,351,11029,774,322,16023,380,719,000
CFO
20.69b
-10.79%
9,578,987,0003,094,032,00018,607,208,00014,538,986,00015,115,299,99021,111,224,30010,666,757,40013,410,382,49015,927,221,68019,824,042,53023,479,839,41017,454,809,81024,730,950,63022,754,682,62035,317,945,23016,851,173,85023,196,782,38020,693,373,000
Dividend
Dec 27, 2023300 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.
URL
https://www.whanin.com/
IPO date
Jul 03, 1996
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT